Taysha Gene Therapies initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Taysha Gene Therapies with an Overweight rating and $9 price target. The company’s lead asset, TSHA-102 , is poised to transform the treatment paradigm for Rett syndrome a rare, genetic neurodevelopmental disorder with a high unmet need, despite the existence of an approved therapy, the analyst tells investors in a research note. With “further derisking data” anticipated near term, the stock is set to “inflect meaningfully higher” as soon as mid-2024, with additional drivers toward year-end, says Piper.